## Incident hepatocellular carcinoma in patients with type 2 diabetes, with and without obesity (Comparison between propensity-score matched cohorts)

Cohort size	Exposure cohort	Comparison cohort	# of cases (overall risk) (Exposure cohort)	# of cases (overall risk) (Comparison cohort)		HR (95% CI)
	Obesity					
21,959	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	17 (0.08%)	60 (0.27%)	<del></del>	0.27 (0.16–0.47)
21,097	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	62 (0.29%)	74 (0.35%)	<b>├─■</b>	0.85 (0.61–1.20)
42,291	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	125 (0.30%)	119 (0.28%)	<b>⊢</b> ■	0.95 (0.74–1.22)
19,007	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	68 (0.36%)	59 (0.31%)	<b>├──■</b> ── <b>│</b>	1.08 (0.76–1.54)
43,523	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	115 (0.26%)	129 (0.30%)	<b>⊢</b> ■	0.83 (0.64–1.06)
19,388	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	62 (0.32%)	40 (0.21%)	-	1.42 (0.96–2.12)
	No obesity					
24,392	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	12 (0.05%)	58 (0.24%)	 ├── <del>-</del>	0.20 (0.11–0.37)
24,945	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	69 (0.28%)	77 (0.31%)	<b>├─■</b>	0.92 (0.67–1.28)
59,166	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	126 (0.21%)	145 (0.25%)	<del>  ■  </del>	0.81 (0.64–1.03)
33,906	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	86 (0.25%)	90 (0.27%)	<b>⊢</b> ■	0.91 (0.68–1.23)
49,323	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	117 (0.24%)	131 (0.27%)	<b>⊢</b> ■	0.85 (0.66–1.09)
42,717	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	110 (0.26%)	93 (0.22%)	H=-1	1.13 (0.86–1.49)
					0.20 0.30 0.500.70 1.0 2.0 3.004.0 Hazard Ratio (HR)	